Combos Deemed Safe, Effective in Recurrent Glioblastoma
Treatment with retifanlimab, bevacizumab, and hypofractionated radiotherapy — with or without epacadostat — appears safe and effective in patients with recurrent glioblastoma.
Related Articles
Unraveling the tumor-initiating cells in hepatocellular carcinoma
Aggressive features of hepatocellular carcinoma (HCC) are highly related to liver tumor-initiating cells (TICs), which are heterogeneous and plastic. In this issue of Cancer Cell,…
Report on Artificial Intelligence and Health Insurance – Consumer Health Reps at NAIC
This report was compiled by NORC at the University of Chicago on behalf of the Consumer Representatives to the NAIC. The report examines the current…
Palliative Care Is Underutilized, May Boost Mental Health in Pancreatic Cancer
Approximately one-third of patients with pancreatic cancer and anxiety had a palliative care consultation, data showed.
Recognizing Lung Cancer Symptoms
Catching cancer early can mean more treatment options and better outcomes. But when it comes to lung cancer, early detection can be a challenge. Symptoms…
Breast Cancer Radiologist Releases Song Encouraging Breast Screening
Average risk women should begin annual screening at age 40
Novel Definition of PPED Helps Predict, Reduce ED Visits Among Oncology Patients – Oncology Nurse Advisor
Characteristics of oncology patients most likely to have a potentially preventable emergency department visit were identified.
Fox Chase Cancer Center Researcher Find New Treatment Targets in Microenvironment of Small Cell Lung Cancer
PHILADELPHIA (November 19, 2024) — A study led by a researcher at Fox Chase Cancer Center provides new insights into the cellular composition and microenvironment…
News
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
OA Virtual conferences
Sorry, your request to load the app is timing out. Please check your internet connection and refresh the page. If the issue continues, try in…
Genetic Test Predicts Survival Benefit From Docetaxel in… : Oncology Times
An abstract is unavailable.
